{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:26:10Z","timestamp":1778905570591,"version":"3.51.4"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873050"],"award-info":[{"award-number":["81873050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011470","name":"Shanghai Minhang Science and Technology Commission","doi-asserted-by":"publisher","award":["2019MHZ112"],"award-info":[{"award-number":["2019MHZ112"]}],"id":[{"id":"10.13039\/501100011470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.taap.2022.115911","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T11:39:07Z","timestamp":1644233947000},"page":"115911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways"],"prefix":"10.1016","volume":"438","author":[{"given":"Jingyun","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baixue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiou","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2022.115911_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.podrm.2018.11.003","article-title":"Sorafenib","volume":"44","author":"Abdelgalil","year":"2019","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"10.1016\/j.taap.2022.115911_bb0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.taap.2022.115911_bb0015","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/cbin.11051","article-title":"Establishment of an in ovo chick embryo yolk sac membrane (YSM) assay for pilot screening of potential angiogenic and anti-angiogenic agents","volume":"42","author":"As","year":"2018","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.taap.2022.115911_bb0020","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-04-1564","article-title":"Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis","volume":"11","author":"Bae","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.semcancer.2009.05.003","article-title":"The angiogenic switch in carcinogenesis","volume":"19","author":"Baeriswyl","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.taap.2022.115911_bb0030","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0035","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2022.115911_bb0040","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2022.115911_bb0045","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.3816\/CLC.2007.s.006","article-title":"Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer","volume":"8","author":"Byers","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2022.115911_bb0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1734-1140(10)70252-8","article-title":"Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression","volume":"62","author":"Chen","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2022.115911_bb0060","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.2147\/IJN.S181928","article-title":"Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide\/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles","volume":"13","author":"Chen","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.taap.2022.115911_bb0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0070","doi-asserted-by":"crossref","first-page":"vii109","DOI":"10.1093\/annonc\/mdl962","article-title":"Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy","volume":"17 Suppl 7","author":"Ciardiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications","volume":"45","author":"Delire","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.taap.2022.115911_bb0080","first-page":"12","article-title":"Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma","author":"Dimri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.taap.2022.115911_bb0085","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1186\/s12885-016-2834-8","article-title":"Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model","volume":"16","author":"Ding","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0090","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S1097-2765(00)80221-X","article-title":"Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability","volume":"4","author":"Eliceiri","year":"1999","journal-title":"Mol. Cell"},{"key":"10.1016\/j.taap.2022.115911_bb0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0100","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2022.115911_bb0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/annonc\/mdh188","article-title":"Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors","volume":"15","author":"Giaccone","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0110","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0115","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/hep.30666","article-title":"Sorafenib induces Pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma","volume":"70","author":"Hage","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2022.115911_bb0120","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"Herbst","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u22122020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","article-title":"Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma","volume":"84","author":"Ito","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0135","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.taap.2022.115911_bb0140","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.bbrc.2012.12.076","article-title":"Vascular endothelial growth factor signaling regulates the segregation of artery and vein via ERK activity during vascular development","volume":"430","author":"Kim","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2022.115911_bb0145","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.taap.2022.115911_bb0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cell.2009.12.046","article-title":"Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development","volume":"140","author":"Lichtenberger","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.taap.2022.115911_bb0155","doi-asserted-by":"crossref","first-page":"71036","DOI":"10.18632\/oncotarget.11954","article-title":"Combination treatment including targeted therapy for advanced hepatocellular carcinoma","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2022.115911_bb0160","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2022.115911_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"Llovet","year":"2021","journal-title":"Hepatocellular carcinoma. Nat Rev Dis Primers"},{"key":"10.1016\/j.taap.2022.115911_bb0170","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1002\/jcp.30080","article-title":"IL-8\/CXCR2 mediates tropism of human bone marrow-derived mesenchymal stem cells toward CD133(+) \/CD44(+) Colon cancer stem cells","volume":"236","author":"Ma","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.taap.2022.115911_bb0175","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-09-1834","article-title":"Advances in targeting SRC in the treatment of breast cancer and other solid malignancies","volume":"16","author":"Mayer","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.510230309","article-title":"Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor","volume":"23","author":"Mise","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2022.115911_bb0185","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3390\/cancers13123026","article-title":"MAPK\/ERK signaling pathway in hepatocellular carcinoma","volume":"13","author":"Moon","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.taap.2022.115911_bb0190","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The role of angiogenesis in hepatocellular carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/375577a0","article-title":"Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation","volume":"375","author":"Mukhopadhyay","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.taap.2022.115911_bb0200","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1007\/s00018-004-4070-7","article-title":"Angiogenesis and signal transduction in endothelial cells","volume":"61","author":"Mu\u00f1oz-Ch\u00e1puli","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.taap.2022.115911_bb0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCRESAHA.108.174128","article-title":"Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt","volume":"103","author":"Nishi","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2022.115911_bb0210","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2022.115911_bb0215","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.taap.2022.115911_bb0220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11912-020-00981-0","article-title":"Combined inhibition of EGFR and VEGF pathways in patients with EGFR-mutated non-small cell lung Cancer: a systematic review and Meta-analysis","volume":"22","author":"Peravali","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.taap.2022.115911_bb0225","first-page":"257","article-title":"Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice","volume":"5","author":"Perrotte","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0230","first-page":"1523","volume":"151","author":"Petit","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2022.115911_bb0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0240","first-page":"1931","article-title":"What do oncogenic mutations have to do with angiogenesis\/vascular dependence of tumors?","volume":"62","author":"Rak","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0245","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bcp.2011.12.025","article-title":"Acquired resistance to drugs targeting receptor tyrosine kinases","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2022.115911_bb0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.taap.2022.115911_bb0255","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.taap.2022.115911_bb0260","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1593\/neo.07667","article-title":"Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice","volume":"9","author":"Sasaki","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.taap.2022.115911_bb0265","first-page":"469","article-title":"Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis","volume":"39","author":"Shibuya","year":"2006","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.taap.2022.115911_bb0270","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2022.115911_bb0275","first-page":"136","article-title":"Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors","volume":"1845","author":"Siveen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2022.115911_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0959-9673.2004.00396.x","article-title":"Current methods for assaying angiogenesis in vitro and in vivo","volume":"85","author":"Staton","year":"2004","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.taap.2022.115911_bb0285","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/clpt.2009.297","article-title":"Targeted cancer therapies in the twenty-first century: lessons from imatinib","volume":"87","author":"Stegmeier","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2022.115911_bb0290","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.biopha.2017.01.090","article-title":"Erianin inhibits indoleamine 2, 3-dioxygenase -induced tumor angiogenesis","volume":"88","author":"Su","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.taap.2022.115911_bb0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.taap.2022.115911_bb0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0305","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.taap.2022.115911_bb0310","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ijc.32936","article-title":"Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma","volume":"147","author":"Tee","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0315","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0046-8177(98)90205-2","article-title":"Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma","volume":"29","author":"Torimura","year":"1998","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.taap.2022.115911_bb0320","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ncponc1161","article-title":"Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications","volume":"5","author":"Tortora","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.taap.2022.115911_bb0325","doi-asserted-by":"crossref","first-page":"13827","DOI":"10.1038\/srep13827","article-title":"Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2","volume":"5","author":"Tu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2022.115911_bb0330","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ijrobp.2003.09.091","article-title":"Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies","volume":"58","author":"Viloria-Petit","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.taap.2022.115911_bb0335","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2022.115911_bb0340","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1002\/jcb.27158","article-title":"The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9","volume":"119","author":"Wang","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.taap.2022.115911_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41540-017-0037-9","article-title":"VEGFR1 promotes cell migration and proliferation through PLC\u03b3 and PI3K pathways","volume":"4","author":"Weddell","year":"2018","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.taap.2022.115911_bb0350","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/1476-4598-13-216","article-title":"Small nucleolar RNA 113-1 suppresses tumorigenesis in hepatocellular carcinoma","volume":"13","author":"Xu","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.taap.2022.115911_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113491","article-title":"Receptor tyrosine kinase-targeted Cancer therapy","volume":"19","author":"Yamaoka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2022.115911_bb0360","doi-asserted-by":"crossref","first-page":"16978","DOI":"10.1002\/jcb.28959","article-title":"Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent","volume":"120","author":"Yuan","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.taap.2022.115911_bb0365","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41388-019-1052-7","article-title":"VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway","volume":"39","author":"Zhangyuan","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.taap.2022.115911_bb0370","first-page":"3149","article-title":"A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition","volume":"5","author":"Zhou","year":"2015","journal-title":"Am. J. Cancer Res."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X22000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:57:50Z","timestamp":1758574670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X22000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":74,"alternative-id":["S0041008X22000564"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2022.115911","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2022.115911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115911"}}